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Abstract
There are several new hot topics in antifungals and antifungal susceptibility testing. In this review, 
four topics of general interest to the clinical microbiology community are discussed. The first 
topic is the introduction of isavuconazole, a new triazole approved for clinical use in the US. The 
second is triazole resistance in Aspergillus fumigatus isolates. A specific set of mutations are 
being found with greater frequency in isolates globally, including the US. The third topic of 
interest is a word of caution about antifungal susceptibility testing for caspofungin in Candida 
isolates; some laboratories have reported susceptible isolates with high MIC values that would be 
interpreted as resistant. The final topic is an introduction to epidemiological cutoff values and their 
use in the clinical mycology laboratory.
Introduction
Antifungal susceptibility testing is not generally a topic at the top of most agendas in the 
clinical microbiology laboratory. Many laboratories do not offer this testing because of the 
expertise required and infrequency with which it is requested. With that in mind, it is 
prudent that a periodic review of what is new in antifungal susceptibility testing be provided. 
Four topics are currently being discussed in antifungal susceptibility testing laboratories. 
The first topic is the introduction of isavuconazole, a new triazole approved for clinical use 
in the US. The second is a new set of mutations within Aspergillus fumigatus isolates that 
confer resistance to azole drugs. These mutations are being found with greater frequency in 
isolates globally, including the US. The third topic of interest is the pitfalls of performing 
antifungal susceptibility testing for caspofungin in Candida isolates. Some laboratories 
report high MIC values that can be interpreted as resistant. The final topic is an introduction 
to epidemiological cutoff values and their use in the clinical mycology laboratory.
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Isavuconazole: A new drug
Compared to the number of antimicrobials available for the treatment of bacterial infections, 
the proverbial “cupboard” of antifungal agents is quite bare. Three classes of antifungal 
agents are available for the treatment of invasive infections: polyenes (amphotericin B), 
echinocandins (caspofungin, micafungin, and anidulafungin), and azoles (fluconazole, 
itraconazole, voriconazole and posaconazole). For primary therapy of mold infections only 
amphotericin B, itraconazole, voriconazole, and posaconazole are considered. For the first 
time since 2006 when posaconazole was released, the US Food and Drug Administration has 
approved the use of a new mold-active antifungal agent, the extended-spectrum triazole 
isavuconazole (trade name CRESEMBA®). Isavuconazole has been approved for the 
treatment of invasive aspergillosis, and it is also the first antifungal agent specifically 
indicated for the treatment of invasive mucormycosis. Isavuconazole is water soluble, 
eliminating the need for potentially toxic diluents, and it is available in both IV and oral 
formulations with no requirement to be taken with food for increased absorption. Like the 
other triazoles, isavuconazole is a lanosterol 14α demethylase inhibitor which blocks 
ergosterol production in fungi, leading to the accumulation of toxic sterol precursors and 
eventually to cell death (1).
In a recent phase 3 randomized double-blind trial of invasive aspergillosis, isavuconazole 
was compared directly to the currently recommended treatment for invasive aspergillosis, 
voriconazole (2). At the end of the trial, isavuconazole was found to be non-inferior to 
voriconazole. Trial patients who received isavuconazole also had significantly fewer drug-
related adverse events and a lower rate of discontinuation of treatment due to those adverse 
events than those patients who received voriconazole (2).
Several studies have looked at the in vitro effectiveness of isavuconazole against 
Mucormycetes (3, 4). In one interesting study the authors performed in vitro susceptibility 
testing on 70 isolates of Mucorales. The in vitro activity of isavuconazole was species 
dependent with good activity against isolates of Lichtheimia, Rhizomucor, and Rhizopus, 
but higher MICs against Mucor circinelloides sensu lato. In lieu of outcome data, the authors 
compared the MIC values of the Mucorales isolates to the wild type range of MIC values for 
Aspergillus fumigatus (in other words, the epidemiological cutoff value, discussed below) 
with the hypothesis that if A. fumigatus isolates could be treated at that MIC value, so could 
Mucorales isolates. They called isolates with MICs in this range “potentially susceptible” 
(pot-S). They found that 80–100% of the isolates of Lichtheimia, Rhizomucor and Rhizopus 
were pot-S while only 11% of Mucor circinelloides isolates were pot-S (3).
Isavuconazole has good in vitro activity against many species of yeast (5–10). It shows 
significant activity against Candida species, Cryptococcus neoformans and C. gattii, 
Rhodotorula, Saccharomyces, and Trichosporon. There is currently a phase 3 clinical trial 
underway to study outcomes in patients with candidemia who are treated with 
isavuconazole. In vitro MIC values against non-Aspergillus, non-Mucormycete molds are 
variable and depend on both the species and the isolate (6, 11). More data are necessary 
before the clinical effectiveness of isavuconazole against these other molds can be 
determined.
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A. fumigatus: A bad bug
Aspergillosis can be a life threatening infection in patients with underlying health conditions 
and is most frequently caused by A. fumigatus (12). Fortunately, effective therapy has been 
available for more than a decade in the form of the triazole class of antifungals. As 
mentioned above, these antifungals target the ergosterol pathway involved in cell membrane 
synthesis, specifically the protein Erg11 which is encoded by the gene cyp51A. As this class 
of antifungal drug is also well tolerated by the patient and is available in both oral and 
intravenous formulations, it represents an ideal therapy for invasive fungal infections and 
one of these antifungals, voriconazole, is recommended as primary therapy for aspergillosis 
(13–15). Unfortunately, resistance to the azoles has been detected in clinical isolates of A. 
fumigatus from various parts of the world, threatening the future use of this primary 
antifungal agent.
The first reports of azole resistant A. fumigatus came from Europe although two of the 
isolates were from US patients (16–18). These early studies indicated that resistance was 
sporadic, rates of azole resistance were approximately 1.7%, and therefore azole resistance 
was still considered an infrequent although troubling occurrence (19). Often the patients 
involved had chronic aspergillus infections and had been undergoing azole therapy for an 
extended period of time, an indication that resistance had evolved under the selective 
pressure of their antifungal regimen. This acquired resistance is in contrast to intrinsic 
antifungal resistance observed in other fungal species, such as fluconazole resistance in 
Candida krusei. Investigation into the mechanisms underlying this azole resistance 
implicated multiple gene mutations within the drug target cyp51A. Clinically relevant 
mutations were found in the codons for multiple amino acids including G54 (read as glycine 
at amino acid number 54), P216, F219, M220, G138, Y431, and G448 (20). The majority of 
these mutations alter the antifungal target in such a way that the drug is no longer able to 
bind efficiently and antifungal activity is lost.
More recently, studies have indicated that the epidemiology of azole resistance in A. 
fumigatus has changed. Patients who are naïve to azole therapy have presented with azole-
resistant aspergillosis with more frequency and the overall rates of azole resistance have 
increased dramatically (21, 22). This change was highlighted first by a 2007 report from the 
Netherlands which described an alarming rate of increased resistance and called for 
international surveillance into this potential health concern (23). Additional studies have 
reported detection of triazole resistance in A. fumigatus from other parts of the world 
including Australia, Europe, Asia, the Middle East, Africa, and South America (24–30). The 
overwhelming majority of these cases were caused by two different cyp51A mutations called 
TR34/L98H and TR46/Y121F/T289A. The TR34/L98H mutation is comprised of a 34 base 
pair tandem repeat in the cyp51A promoter region and a L98H (Lysine 98 to histidine) 
polymorphism within the Cyp51A amino acid sequence. Similarly, TR46/Y121F/T289A is 
comprised of a 46 base pair tandem repeat in the cyp51A promoter region and two 
polymorphisms within the Cyp51A amino acid sequence. These two mutations confer cross 
resistance to multiple azoles (31).
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There is evidence that the TR34/L98H and TR46/Y121F/T289A mutations have an 
environmental origin (32, 33). Aspergillus species are ubiquitous in nature and grow well in 
soil, around decomposing plants, and in areas of crop production (12). When azole 
fungicides are applied to protect agricultural plants from fungal pathogens, A. fumigatus is 
also exposed, providing opportunity for this pathogen to undergo genetic changes to 
overcome the stress caused by these fungicides. This is similar to the selection for resistance 
that occurs with drug exposure in a patient. Evidence for environmental selection includes 
the finding of this mutation in azole resistant A. fumigatus isolates cultured from soil and 
cultured from azole-naïve patients (28–30).
The TR34/L98H and TR46/Y121F/T289A mutations have only recently been identified 
within the US. In a study of 1,026 A. fumigatus isolates collected from across the US 
between 2011 and 2013 neither of these mutations was detected in any isolates (34). 
However, two recent reports showed that two isolates with TR34/L98H were collected from 
patients in Pennsylvania in 2010 and 2012 and isolates with TR46 Y121F/T289A were 
collected from patients in Arizona in 2008 and Michigan in 2014 (35, 36). This alarming 
discovery signifies that this emerging health problem is no longer only a concern in other 
parts of the world but in the US as well.
In the US, antifungal breakpoints to molds have not been determined, so resistance to a 
triazole antifungal is defined as an MIC that exceeds the established epidemiological cutoff 
value (see below). Elevated MICs are associated with poorer patient outcomes and 
complicate patient management by restricting therapeutic options. However, antifungal 
susceptibility testing is not often routinely performed in clinical microbiology laboratories 
and sending out for susceptibility testing results in long turn-around-times. When testing is 
performed, standard procedures require positive fungal culture, which may be difficult to 
obtain. This compounds the challenge of surveillance and resistance detection, and perhaps 
contributes to underrepresented true rates of azole resistant A. fumigatus.
Both environmental- and patient-based azole resistance in A. fumigatus continue to evolve 
globally as a public health challenge, a fact which is underscored by the remarkable shift in 
rates of resistance which has occurred in recent years. Moreover, the number of drugs in the 
development pipeline are few. In order to preserve the utility of available therapies, it is vital 
that we understand the evolution of azole resistance and assess its prevalence within the 
clinical population. To this end, the Centers for Disease Control and Prevention is 
conducting surveillance for azole resistant A. fumigatus. More information about this 
surveillance can be found here: http://www.cdc.gov/fungal/diseases/aspergillosis/index.html.
Sweeping caspofungin testing under the rug
The echinocandins are the newest class of antifungal agents and they are considered first line 
therapy for infections with Candida species (37, 38). There are three echinocandins available 
for clinical use: caspofungin, micafungin and anidulafungin. The Clinical and Laboratory 
Standards Institute (CLSI) has established breakpoints for resistance for all three 
echinocandins against Candida albicans, C. tropicalis, C. parapsilosis, C. krusei, C. glabrata, 
and C. guilliermondii (39). However, when using broth microdilution, some laboratories 
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have experienced caspofungin MIC values that are higher than other laboratories and give 
the impression that most of the Candida isolates tested are caspofungin resistant (40, 41). 
This is not seen when testing the same isolates with micafungin or anidulafungin. Although 
some studies have attempted to determine the cause of this discrepancy such as testing 
different lots of caspofungin and using different types of microtiter plates, the overall cause 
has remained elusive (42). This phenomenon is an in vitro artifact and has no bearing on the 
clinical treatment of patients: there is no evidence that an isolate can be resistant to one 
echinocandin but susceptible to another. However, due to the interlaboratory variability 
when testing with caspofungin the European Committee on Antimicrobial Susceptibility 
Testing declined to establish breakpoints for caspofungin (43).
There are several alternatives to using microbroth dilution testing for caspofungin resistance. 
The first is to use micafungin or anidulafungin as a surrogate for testing against caspofungin. 
Surrogate testing is often used in susceptibility testing for bacteria and two studies show that 
it should be successful for Candida and the echinocandins as well (44, 45). Another 
alternative would be to perform susceptibility testing using the YeastOne® panel. While 
YeastOne® does not strictly follow the protocols outlined in the CLSI guidelines for broth 
microdilution susceptibility testing, the phenomenon of higher than normal caspofungin 
MIC values is not seen when testing using the YeastOne® panel (46, 47). In contrast, there is 
some evidence that this phenomenon may also apply to testing using Etest® so this cannot 
be recommended as an alternative (48). Given that there are viable alternatives, microbroth 
dilution susceptibility testing of Candida against caspofungin as outlined in CLSI M27-A3 is 
not currently recommended.
Solving the ECV shrug
When confronted with the concept of epidemiological cutoff values (ECVs) many lab 
directors and clinicians, shrug their shoulders and say “I don’t know what to do with these!” 
In the next few paragraphs we will introduce the concept of ECVs and explain why they are 
needed and how they should be used. This introduction will hopefully prepare directors, 
clinicians, and technologists for their use with fungi.
Why don’t we just keep establishing breakpoints?
In order to establish a breakpoint for any fungus/antifungal combination a number of things 
are needed: the MIC distribution of a large number of isolates, the pharmacokinetics/
pharmacodynamics of the drug, and patient outcome data for a patient population treated 
with a specific dose of that antifungal. The MIC distribution data is the easiest to obtain, 
simply requiring testing of multiple isolates of the species against the drug of interest and 
recording the distribution of values. The pharmacokinetics/pharmacodynamics are not as 
easy. They can be determined using an animal model of infection, using healthy volunteers, 
or during intensive monitoring of a patient population during treatment. All of these are 
invasive, costly, and difficult with some of the rare fungal species that might only be seen 
once a year or less in any given institution. The last piece of necessary information for 
establishing a breakpoint is clinical outcome data. In general, this data is generated during a 
controlled clinical trial. Clinical trials are established in a relatively small number of 
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institutions, and for many fungus/antifungal combinations there would simply not be enough 
cases to justify the effort and the tremendous cost. Outcome data can be generated outside of 
a clinical trial, but without patient population and treatment controls in place, the usefulness 
of this data is suspect. What all of this means is that there will probably never be any 
breakpoints for many fungus/antifungal combinations.
What do we do without breakpoints?
Without the benefit of breakpoints, clinicians rely on published case reports and institutional 
knowledge when deciding how to treat a particular patient. One of the central questions 
around treatment is what to do when a patient is failing therapy. Is the failure due to host 
factors or is the failure due to the drug not being effective against the fungus? How do we 
know if the isolate is resistant when there are no breakpoints to establish a definition for 
resistance? Often a clinician will ask for susceptibility testing, but the result is a set of 
numbers with no interpretive criteria. While the definition for resistance (i.e. the breakpoint) 
may not be available, there is a way to establish whether a particular isolate is wild type (i.e. 
without an acquired mechanism of resistance) in terms of susceptibility to a given antifungal 
agent and that is by comparing the MIC value of the isolate to the ECV.
What is an ECV?
An ECV is an MIC value that defines the upper limit of the wild type distribution of MIC 
values for any particular fungus/antifungal combination. An ECV indicates when an MIC 
value for a particular fungus/antifungal combination either looks like a “normal” (wild type) 
MIC value or it looks like a value that is higher than normal (non-wild type). An MIC value 
that is higher than normal may indicate antifungal resistance.
To establish an epidemiological cutoff value all that is needed is the distribution of MIC 
values for a particular fungus/antifungal combination. In the new CLSI document M57 the 
data requirement for establishing an ECV is 100 individual data points (fungus/antifungal 
MIC values) collected from at least three different laboratories, and generated using the 
established CLSI criteria (CLSI, in preparation). The endpoint for the wild type MIC 
distribution is established using a statistical algorithm that defines the endpoint 
encompassing 97.5% of the “modeled” distribution. The algorithm is not a straight MIC97.5; 
in other words, it doesn’t just draw a line at the MIC under which 97.5% of the values lie. 
The algorithm gives higher weight to the values around the modal MIC (the MIC value with 
the highest number of isolates) so that having isolates that are not wild type in the data set 
does not skew the data to a higher MIC value (49).
For species with known mechanisms of antifungal resistance, the ECV can be tested by 
plotting the distribution of isolates that are known to be wild type against those that have a 
known mechanism of resistance. Figure 1 shows the distribution of Candida glabrata isolates 
that are known to be susceptible to micafungin against those known to have FKS mutation-
mediated resistance to micafungin. While 1.7% of the wild type isolates have an MIC value 
above the ECV (determined to be 0.03 μg/ml (50)), no isolates with known mechanisms of 
resistance have an MIC value that falls below the ECV. It is possible that some of the wild 
type isolates with MIC values above the ECV have an unknown mechanism of resistance 
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and are not truly wild type, but in any case, using the established ECV only 1.7% of the 
susceptible isolates are defined as non-wild type, and none of the resistant isolates are 
defined as wild type.
ECVs have been generated for a number of fungus/antifungal combinations using 
surveillance isolates as well as using combined data sets from multiple laboratories (50–62). 
While these ECVs are useful and quite often accurate, they were not established using a 
single set of defined criteria. The goal of CLSI document M-57 is to create a defined set of 
criteria for the establishment of fungal ECVs as well as to generate and publish ECV values 
for fungus/antifungal combinations for which there are no current breakpoints. This will 
include yeasts as well as molds.
How should ECVs be used?
Epidemiological cutoff values were not established as a replacement for breakpoints. 
However, they can be a useful tool in clinical decision making. In a laboratory information 
system (LIS) report, the MIC of a given fungus/antifungal combination can be provided to 
the clinician along with the ECV and a note that no breakpoints or interpretive criteria exist. 
If the MIC is above the ECV a comment can be added to the LIS report that the MIC is 
above the wild type MIC for that species and the isolate may have an acquired mechanism of 
resistance. The clinician will still be dependent upon institutional knowledge of how to 
typically treat the species in question, but MIC value in relation to the ECV may be another 
helpful piece of information, especially when the patient is not responding to therapy. An 
ECV is not a panacea for a lack of an established breakpoint, but it is an available tool that 
may assist in decision making for use of a particular antifungal agent against a particular 
isolate.
Summary
While changes in the clinical mycology laboratory do not happen at the same rate as changes 
in the bacteriology laboratory, there are changes in protocols, new antifungals in the 
armamentarium, and new resistance mechanisms appearing. Laboratories should be aware 
that clinicians may request susceptibility testing against the newest antifungal, 
isavuconazole. Testing may be requested to confirm or rule out triazole resistance in 
Aspergillus fumigatus isolates. And finally, new data are forthcoming in the form of ECVs 
that will allow the inclusion of some interpretive criteria for fungus/antifungal combinations 
for which there are no breakpoints.
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Figure 1. 
Micafungin MIC distribution of 1,380 isolates of C. glabrata. The white bars represent wild 
type isolates, and the black bars represent isolates with FKS mutation-mediated resistance to 
micafungin. Note that the ECV (0.03 μg/ml; black arrow) accurately defines the cutoff for 
isolates with known mechanisms of resistance.
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